ReviewAnnals of medicine and surgery (2012)2024

Frexalimab (SAR441344) as a potential multiautoimmune disorder tackling mAB targeting the CD40-CD40L pathway undergoing clinical trials: a review.

Tehreem Fatima et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.